Navigation Links
Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial

A total of 332 de novo (newly transplanted) kidney transplant patients will be enrolled in this trial. Patients will be placed into one of four separate treatment groups; three different dose groups of ISA247 (0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily compared with the fourth group, a tacrolimus (0.05 mg/kg twice daily) control arm. Patients in all four treatment groups will have their doses adjusted in order to achieve pre-defined blood levels of either ISA247 or tacrolimus. All patients will receive oral treatment of drug (ISA247 or tacrolimus) over a six month period along with other standard immunosuppressive therapies used following transplantation.

About Isotechnika

-----------------

Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isotechnika looks to become the leader in development of immunosuppressant therapies. Isotechnika's lead drug, ISA247, has successfully completed a Phase 3 Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase 3 European/Canadian psoriasis trial and a Phase 2b North American trial for the prevention of kidney graft rejection. One of our partners, Lux Biosciences, has received permission from the Food and Drug Administration to investigate ISA247 in three separate pivotal Phase 2/Phase 3 trials for the treatment of non-infectious uveitis and as a maintenance therapy in uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at www.isotechnika.com.

Partnerships

------------

Isotechnika Inc. signed a collaboration agreement with Hoffman La Roche on April 9, 2002, which licensed the worldwide righ
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... , Sept. 19, 2014  PCI is ... International (Biotec).  Biotec is a leading provider of ... headquartered in Bridgend, Wales ...  The addition significantly expands PCI,s presence in the ... products by adding packaging, storage and distribution capacity, ...
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
Breaking Medicine Technology:First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... June 8, 2011 Medco Health Solutions, Inc. (NYSE: ... its groundbreaking SOCRxATES® community pharmacy program to ... SOCRxATES is a care improvement program that enables ... medical conditions and gaps in care, such as medication ...
... 2011 CANTEL MEDICAL CORP. (NYSE: CMN ... $0.29 per diluted share, on a 24% increase in sales to ... This compares with net income of $4,274,000, or $0.25 per diluted ... 30, 2010.  For the nine months ended April 30, 2011, the ...
Cached Medicine Technology:Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5
(Date:9/21/2014)... The prevalence of preterm birth the birth of ... is a significant health problem that has increased over ... for Disease Control and Prevention (CDC), preterm birth affects ... eight born in the U.S. While medical care has ... ways to positively impact the neurodevelopmental outcomes of preterm ...
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... 22, 2014 PhUSE is proud to ... Lilliam Rosario as keynote speakers for their 10th annual ... Dr. Ben Goldacre in 2013 , Charles ... in 2011 , PhUSE again presents high-calibre speakers to ... about advancement of clinical information. , Dr. Pritpal Tamber ...
(Date:9/21/2014)... September 21, 2014 The Laboratory Testing ... and manufacturers perform tests on items ranging from consumer ... regulated society, pressure on operators to ensure the safety ... A greater number of government safety regulations and consumer ... prior to sale. Although revenue briefly dipped in 2009 ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... shown to prevent the transmission of HIV as well. Experiments ... or reduce the painful open sores of chancroid on the ... ,Chancroid is a highly contagious STD that is ... United States as well. Antibiotics can be used to effectively ...
... are considered to be a high tech machine and are ... working hard to make it otherwise//. There is a big ... and confusion. Dr J?rg Voskamp, from Germany's Fraunhofer Institute plans ... one’s emotions. A sensitive PC is a research project and ...
... a baby was stillborn last week. But the baby was alive ... before finally succumbing on Saturday. ,Born to Rakesh and ... Rakesh, an auto driver, took him to the burial ground, the ... intensive care unit of the hospital. ,The baby was delivered ...
... A married couple who tried to hoodwink authorities by tying ... collect Rs 5000/- as a reward have been hauled away ... were married 15 years ago and have three children. ... government's mass marriage promotion scheme under which Rs.5,000 is given ...
... 14 which is marked for the celebration of Mother’s day ... India. According to the statistics released by UNICEF// in India ... the world scenario this accounts to more than 20% of ... births there are about 540 maternal deaths. ,There ...
... were investigating eight suspected bird flu cases in humans in ... had been fatal. ,A team from the WHO ... can say they are still suspect at the moment," said ... the Health Ministry's office of communicable disease control, added that ...
Cached Medicine News:Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 2Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 3
... Auto Suture™ PREMIUM SURGICLIP™ clip applier consists of ... cartridge containing 15 or 20 titanium clips. , ... a vessel or other tubular structure. As the ... clip is closed around the vessel or structure. ...
... single use stapler places two titanium staples ... and a knife which divides the tissue ... ,The Auto Suture™ Powered LDS™ single use ... abdominal, gynecological, orthopedic, and thoracic surgery for ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
... 20/20 Multiple Clip Applier is a sterile ... This automatic instrument is preloaded with 20 ... by means of the unique Klieman feed ... is reloadable once with a reload containing ...
Medicine Products: